Search - tctmd.com

Displaying 421 - 440 of 4990

Sort: Relevancy | Date

Presentation TCT 2016

Individual and Programmatic CTO Development: Lessons Learned the Hard Way

Presenter: James C. Spratt, Simon J. Walsh, Steven P. Marso

October 31, 2016

Presentation TCT 2016

ABSORB China Clinical Outcomes at 2 Years

Presenter: Stephen G. Ellis, Corrado Tamburino, Runlin Gao

October 31, 2016

Presentation TCT 2016

Trial #3 - The Essentials of ... the LEADERS FREE trial

Presenter: Sunil V. Rao, Harvey D. White, Philip M. Urban

October 31, 2016

Presentation TCT 2016

Making Sense: From Risk Scores to Triage Left Main Patients to PCI vs CABG

Presenter: Seung-Jung Park, Leif Thuesen, Davide Capodanno

October 31, 2016

Presentation TCT 2016

ABSORB II Clinical Outcomes at 3 Years

Presenter: Stephen G. Ellis, Corrado Tamburino, Bernard R. Chevalier

October 31, 2016

Presentation TCT 2016

Featured Lecture: Mitigating Legal Risk in Higher-Risk Coronary Procedures

Presenter: Emmanouil S. Brilakis, Jeffrey W. Moses, Elizabeth A. Leedom

October 31, 2016

Presentation TCT 2016

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

Presenter: Stephen G. Ellis, Corrado Tamburino, Patrick W. Serruys

October 31, 2016

Presentation TCT 2016

Case Presentation: Multivessel Disease in a Patient With Large Inferior STEMI With RCA Culprit and Proximal LAD Non-Culprit Lesion

Presenter: Ran Kornowski, Michel R. Le May, Natalia Pinilla-Echeverri

October 31, 2016

Presentation TCT 2016

How to Establish and Grow a CTO Program: Essentials and Pitfalls

Presenter: James C. Spratt, Simon J. Walsh, Farouc Jaffer

October 31, 2016

Presentation TCT 2016

Building the CHIP Heart Team: Institutional and Network Strategies for a Successful CHIP Program

Presenter: Emmanouil S. Brilakis, Jeffrey W. Moses, Jonathan M. Hill

October 31, 2016

Presentation TCT 2016

Pre-EXCEL and NOBLE: What Have We Learned From Contemporary Left Main Randomized Trials?

Presenter: Seung-Jung Park, Leif Thuesen, Marie-Claude Morice

October 31, 2016

Presentation TCT 2016

MATRIX Critique: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, Frederick Feit

October 31, 2016

Presentation TCT 2016

DEBATE: Predicting Thrombotic Events in Patients With STEMI and Multivessel Disease: Vulnerable Plaque Is the Single Most Important Factor!

Presenter: Ran Kornowski, Michel R. Le May, Tej Sheth

October 31, 2016

Presentation TCT 2016

Early Insights From the DELTA-2 Registry

Presenter: Seung-Jung Park, Leif Thuesen, Alaide Chieffo

October 31, 2016

Presentation TCT 2016

Clinical Risk Assessment and Health Status Goals in the CHIP Population

Presenter: Emmanouil S. Brilakis, Jeffrey W. Moses, Adam C. Salisbury

October 31, 2016

Presentation TCT 2016

Acute Cardiogenic Shock Treatment Algorithm 3: The Case for First-line Use of ECMO

Presenter: Simon R. Dixon, Holger Thiele, A. Reshad Garan

October 31, 2016

Presentation TCT 2016

Failure Modes of Bioresorbable Scaffolds: From the Obvious (Strut Thickness Considerations) to the Novel (Intraluminal Scaffold Dismantling)

Presenter: Elazer R. Edelman, Juan F. Granada

October 31, 2016

Presentation TCT 2016

What Have We Learned From Contemporary Left Main Observational Studies IV? FLORENCE-LM Registry

Presenter: Seung-Jung Park, Leif Thuesen, David Antoniucci (RETIRED)

October 31, 2016

Presentation TCT 2016

Trial #2 - The Essentials of ... the MATRIX Trial Access Site and Anticoagulation Type (And Infusion Duration) in ACS

Presenter: Sunil V. Rao, Harvey D. White, Salvatore Brugaletta

October 31, 2016

Presentation TCT 2016

DEBATE: Predicting Thrombotic Events in Patients With STEMI and Multivessel Disease: The Degree of Stenosis/Ischemia Is Most Important!

Presenter: Ran Kornowski, Michel R. Le May, Anthony H. Gershlick

October 31, 2016

Advertisement

Individual and Programmatic CTO Development: Lessons Learned the Hard Way

ABSORB China Clinical Outcomes at 2 Years

Trial #3 - The Essentials of ... the LEADERS FREE trial

Making Sense: From Risk Scores to Triage Left Main Patients to PCI vs CABG

ABSORB II Clinical Outcomes at 3 Years

Featured Lecture: Mitigating Legal Risk in Higher-Risk Coronary Procedures

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

Case Presentation: Multivessel Disease in a Patient With Large Inferior STEMI With RCA Culprit and Proximal LAD Non-Culprit Lesion

How to Establish and Grow a CTO Program: Essentials and Pitfalls

Building the CHIP Heart Team: Institutional and Network Strategies for a Successful CHIP Program

Pre-EXCEL and NOBLE: What Have We Learned From Contemporary Left Main Randomized Trials?

MATRIX Critique: Pros and Cons

DEBATE: Predicting Thrombotic Events in Patients With STEMI and Multivessel Disease: Vulnerable Plaque Is the Single Most Important Factor!

Early Insights From the DELTA-2 Registry

Clinical Risk Assessment and Health Status Goals in the CHIP Population

Acute Cardiogenic Shock Treatment Algorithm 3: The Case for First-line Use of ECMO

Failure Modes of Bioresorbable Scaffolds: From the Obvious (Strut Thickness Considerations) to the Novel (Intraluminal Scaffold Dismantling)

What Have We Learned From Contemporary Left Main Observational Studies IV? FLORENCE-LM Registry

Trial #2 - The Essentials of ... the MATRIX Trial Access Site and Anticoagulation Type (And Infusion Duration) in ACS

DEBATE: Predicting Thrombotic Events in Patients With STEMI and Multivessel Disease: The Degree of Stenosis/Ischemia Is Most Important!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content